Current treatment strategies for ovarian cancer in the East Asian Gynecologic Oncology Trial Group (EAGOT) DOI Creative Commons
Yusuke Kobayashi, Muneaki Shimada, Masato Tamate

и другие.

Journal of Gynecologic Oncology, Год журнала: 2024, Номер 35(3)

Опубликована: Янв. 1, 2024

Ovarian cancer, notable for its severe prognosis among gynecologic cancers, has seen substantial progress in treatment approaches recently. Enhanced protocols chemotherapy and the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors maintenance therapy have markedly improved outcomes patients with specific genetic profiles, such as those positive BRCA mutations or exhibiting homologous recombination deficiency (HRD). Additionally, method intraperitoneal administration emerged a valuable alternative to traditional transvenous routes, showing promise wider clinical adoption. The field surgery also evolved, increasing exploration into benefits feasibility laparoscopic methods over more invasive surgeries, aiming complete tumor removal but reduced patient impact. hereditary nature ovarian cancer underscores importance testing, which become integral tailoring strategies, particularly determining suitability PARP inhibitors. formation East Asian Gynecologic Oncology Trial Group (EAGOT) aims optimize across Japan, Korea, China, Taiwan. committee EAGOT shared current policies, focusing on 5 topics: 1) strategies after initial chemotherapy, 2) drug regimens platinum-sensitive platinum-resistant recurrence, 3) 4) an laparotomy, 5) status testing (BRCA, HRD, panel tests) prospects. EAGOT's multi-national trials aim harmonize these evolving ensuring that latest most effective are accessible region, thereby significantly impacting Asia.

Язык: Английский

Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up DOI Creative Commons
Antonio González‐Martín, Philipp Harter, Alexandra Léary

и другие.

Annals of Oncology, Год журнала: 2023, Номер 34(10), С. 833 - 848

Опубликована: Авг. 17, 2023

Язык: Английский

Процитировано

166
PARP Inhibitors in Ovarian Cancer: A Review DOI Creative Commons
David M. O’Malley,

Thomas C. Krivak,

Nashwa Kabil

и другие.

Targeted Oncology, Год журнала: 2023, Номер 18(4), С. 471 - 503

Опубликована: Июнь 3, 2023

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the ovarian cancer (OC) treatment landscape. This narrative review provides a comprehensive overview of data for PARPis olaparib, niraparib, and rucaparib in patients with OC discusses their role disease management, focus on use as maintenance therapy United States (US). Olaparib was first PARPi to be approved first-line monotherapy US, niraparib subsequently setting. Data also support efficacy monotherapy. combination (olaparib plus bevacizumab) benefit newly diagnosed advanced whose tumors tested positive homologous recombination deficiency (HRD). Biomarker testing is critical setting identify most likely from guide decisions. Clinical trial (olaparib, rucaparib) second-line or later platinum-sensitive relapsed OC. Although distinct differences tolerability profile were observed between PARPis, they generally well tolerated, majority adverse events managed by dose modification. had no detrimental effect patients' health-related quality life. Real-world OC, although some are apparent. trials investigating novel strategies, such immune checkpoint inhibitors, awaited interest; optimal sequencing therapies remains established.

Язык: Английский

Процитировано

86
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial DOI Creative Commons
Éric Pujade-Lauraine, Frédèric Selle, Giovanni Scambia

и другие.

Annals of Oncology, Год журнала: 2023, Номер 34(12), С. 1152 - 1164

Опубликована: Окт. 4, 2023

Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated efficacy and safety PARP rechallenge.

Язык: Английский

Процитировано

73
Circulating tumor cells: from new biological insights to clinical practice DOI Creative Commons
Xuyu Gu, Shiyou Wei,

Xin Lv

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2024, Номер 9(1)

Опубликована: Сен. 2, 2024

Abstract The primary reason for high mortality rates among cancer patients is metastasis, where tumor cells migrate through the bloodstream from original site to other parts of body. Recent advancements in technology have significantly enhanced our comprehension mechanisms behind bloodborne spread circulating (CTCs). One critical process, DNA methylation, regulates gene expression and chromosome stability, thus maintaining dynamic equilibrium Global hypomethylation locus-specific hypermethylation are examples changes methylation patterns that pivotal carcinogenesis. This comprehensive review first provides an overview various processes contribute formation CTCs, including epithelial-mesenchymal transition (EMT), immune surveillance, colonization. We then conduct in-depth analysis how modifications within CTCs impact each these stages during CTC dissemination. Furthermore, we explored potential clinical implications with cancer. By understanding epigenetic modifications, can gain insights into metastatic process identify new biomarkers early detection, prognosis, targeted therapies. aims bridge gap between basic research application, highlighting significance context metastasis offering avenues improving patient outcomes.

Язык: Английский

Процитировано

37
Mechanism of PARP inhibitor resistance and potential overcoming strategies DOI Creative Commons
Xiaoyu Fu, Ping Li, Qi Zhou

и другие.

Genes & Diseases, Год журнала: 2023, Номер 11(1), С. 306 - 320

Опубликована: Март 24, 2023

PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing DNA single-strand break repair process. Despite significant therapeutic effect in patients with homologous recombination (HR) deficiency, innate and acquired resistance main challenge clinic. In this review, we mainly discussed underlying mechanisms summarized promising solutions overcome resistance, aiming at extending application improving patient outcomes.

Язык: Английский

Процитировано

32
Treatment Approaches for Platinum-Resistant Ovarian Cancer DOI
Jessica D. St. Laurent, Joyce F. Liu

Journal of Clinical Oncology, Год журнала: 2023, Номер 42(2), С. 127 - 133

Опубликована: Ноя. 1, 2023

Journal

Язык: Английский

Процитировано

29
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients DOI Creative Commons

Thibault Gauduchon,

Maria Kfoury, Domenica Lorusso

и другие.

Gynecologic Oncology, Год журнала: 2023, Номер 173, С. 98 - 105

Опубликована: Апрель 25, 2023

Язык: Английский

Процитировано

28
Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions DOI Creative Commons
Giuseppe Caruso, Federica Tomao, Gabriella Parma

и другие.

International Journal of Gynecological Cancer, Год журнала: 2023, Номер 33(4), С. 431 - 443

Опубликована: Март 16, 2023

Poly (ADP-ribose) polymerase inhibitors (PARPi) represent a new standard of care in the upfront treatment advanced epithelial ovarian cancer to point that vast majority patients now receive PARPi, alone or combination with anti-angiogenic bevacizumab, as part their first-line maintenance therapy. The clinical benefit PARPi is well established; however, much has changed since introduction and several relevant questions have been raised remain unresolved post-PARPi era. decision-making process regarding most appropriate therapy could be challenging practice, especially homologous recombination-proficient setting, other factors need considered apart from mutational status. Concerns progression emerged, highlighting an unmet define valid algorithm strategy. may not only compromise response further platinum due cross-resistance mechanisms but impact on subsequent non-platinum chemotherapy surgery also remains unclear. Definitive results role rechallenge are awaited, case oligoprogression managed locoregional treatment. Moreover, updated overall survival data recurrent setting warrant caution using single agents for unselected patients. Several regimens emerging overcoming resistance become our therapeutic armamentarium. This review discusses set clinically issues era provides glimpse future challenges opportunities

Язык: Английский

Процитировано

27
Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights DOI Creative Commons

V. Tuninetti,

Juan A. Marín‐Jiménez, Giorgio Valabrega

и другие.

ESMO Open, Год журнала: 2024, Номер 9(11), С. 103984 - 103984

Опубликована: Ноя. 1, 2024

Poly-ADP-ribose polymerase inhibitors (PARPis) have revolutionized the management of BRCA-mutated (BRCA

Язык: Английский

Процитировано

12
BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges DOI Creative Commons
L. Collet,

Brunhilde Hanvic,

Margherita Turinetto

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Март 13, 2024

BRCA1/2 genes are part of homologous recombination (HR) DNA repair pathways in charge error-free double-strand break (DSB) repair. Loss-of-function mutations have been associated for a long time with breast and ovarian cancer hereditary syndrome. Recently, polyadenosine diphosphate–ribose polymerase inhibitors (PARPi) revolutionized the therapeutic landscape -mutated tumors, especially high-grade serous (HGSC), taking advantage HR deficiency through synthetic lethality concept. However, PARPi efficiency differs among patients, most them will develop resistance, particularly relapse setting. In current proposal, we aim to review primary secondary resistance HGSC owing alterations. Of note, as several mechanisms or described, reversion that restore by far reported. First, type location mutation platinum-salt sensitivity impact probability occurrence mutation. Furthermore, presence multiple variation allelic frequency under treatment underline role intratumor heterogeneity (ITH) resistance. circulating tumor might help us detect characterize ITH finally refine strategy. Importantly, forthcoming strategies, including combination antiangiogenics targeted therapies, may delay overcome mutations. Also, progression despite therapy does not preclude rechallenge selected patients.

Язык: Английский

Процитировано

11